Publikationen

Lin Y, Irmscher S, Skerka C (2019) Monitoring surface reactions by combined western blot-ELISA analysis. Methods Mol Biol 1834, 75-83.
Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W, Schmitz J, Schwarz A, Ivanyi P, Steinmetz OM, Reinhard L, Hoxha E, Zipfel PF, Bräsen JH, Wiech T (2019) Bevacizumab-associated glomerular microangiopathy. Mod Pathol 32(5), 684-700.
Person F, Zipfel PF, Wiech T (2019) Thrombotische Mikroangiopathie: Was gibt es Neues? Der Nephrologe 14(1), 26-31. (Review)
Röttgerding F, Wagemakers A, Koetsveld J, Fingerle V, Kirschfink M, Hovius JW, Zipfel PF, Wallich R, Kraiczy P (2019) Author Correction: Immune evasion of Borrelia miyamotoi: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties. Sci Rep 9(1), 7056.
Schaumburg F, Witten A, Flamen A, Stoll M, Alabi AS, Kremsner PG, Löffler B, Zipfel PF, Velavan TP, Peters G (2019) Complement 5a receptor polymorphisms are associated with PVL-positive Staphylococcus aureus colonization in African Pygmies. Clin Infec Dis 68(5), 854-856.
Schieferdecker S, Shabuer G, Letztel AC, Urbansky B, Ishida-Ito M, Ishida K, Cyrulies M, Dahse HM, Pidot S, Hertweck C (2019) Biosynthesis of diverse antimicrobial and antiproliferative acyloins in anaerobic bacteria. ACS Chem Biol 14(7), 1490-1497.
Smith RJH, Appel GB, Blom AM, Cook HT, D’Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM (2019) C3 glomerulopathy – Understanding a rare complement-driven renal disease. Nat Rev Nephrol 15(3), 129-143. (Review)
Sree KS, Dahse HM, Chandran JN, Schneider B, Jahreis G, Appenroth KJ (2019) Duckweed for human nutrition: No cytotoxic and no anti-proliferative effects on human cell lines. Plant Foods Hum Nutr 74(2), 223-224.
Top O, Parsons J, Bohlender LL, Michelfelder S, Kopp P, Busch-Steenberg C, Hoernstein SNW, Zipfel PF, Häffner K, Reski R, Decker EL (2019) Recombinant production of MFHR1, a novel synthetic multitarget complement inhibitor, in moss bioreactors. Front Plant Sc 10, 260.
Trottmann F, Franke J, Richter I, Ishida K, Cyrulies M, Dahse HM, Regestein L, Hertweck C (2019) Cyclopropanol warhead in malleicyprol confers virulence of human- and animal-pathogenic Burkholderia species. Angew Chem Int Ed 58(40), 14129-14133.